Biohaven (BHVN) Competitors $44.39 -4.27 (-8.78%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BHVN vs. TEVA, BGNE, MRNA, SMMT, VTRS, GMAB, PCVX, RDY, SRPT, and CTLTShould you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Summit Therapeutics (SMMT), Viatris (VTRS), Genmab A/S (GMAB), Vaxcyte (PCVX), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Biohaven vs. Teva Pharmaceutical Industries BeiGene Moderna Summit Therapeutics Viatris Genmab A/S Vaxcyte Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Teva Pharmaceutical Industries (NYSE:TEVA) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Which has more risk and volatility, TEVA or BHVN? Teva Pharmaceutical Industries has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Do analysts recommend TEVA or BHVN? Teva Pharmaceutical Industries presently has a consensus price target of $19.67, suggesting a potential upside of 19.70%. Biohaven has a consensus price target of $63.42, suggesting a potential upside of 42.86%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Biohaven 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07 Do insiders & institutionals believe in TEVA or BHVN? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is TEVA or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Biohaven N/A -225.12%-158.89% Does the MarketBeat Community favor TEVA or BHVN? Teva Pharmaceutical Industries received 929 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 67.77% of users gave Teva Pharmaceutical Industries an outperform vote while only 66.89% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% BiohavenOutperform Votes39666.89% Underperform Votes19633.11% Does the media refer more to TEVA or BHVN? In the previous week, Biohaven had 8 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 17 mentions for Biohaven and 9 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.97 beat Biohaven's score of 0.21 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, TEVA or BHVN? Biohaven has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$15.85B1.17-$559M-$0.85-19.33Biohaven$462.51M9.71-$408.17M-$9.35-4.75 SummaryBiohaven beats Teva Pharmaceutical Industries on 12 of the 19 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Biohaven News Delivered to You Automatically Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHVN vs. The Competition Export to ExcelMetricBiohavenPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.49B$6.39B$5.06B$19.83BDividend YieldN/A8.04%5.06%3.50%P/E Ratio-4.7510.0598.5041.76Price / Sales9.71266.581,205.7320.68Price / CashN/A53.4940.6921.65Price / Book14.239.306.324.66Net Income-$408.17M$154.14M$119.47M$983.45M7 Day Performance-16.98%-9.49%-5.11%-2.12%1 Month Performance-13.72%-7.23%-3.21%-0.47%1 Year Performance49.61%30.70%32.41%24.69% Biohaven Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHVNBiohaven3.811 of 5 stars$44.39-8.8%$63.42+42.9%+49.6%$4.49B$462.51M-4.75239Earnings ReportAnalyst ForecastNews CoverageTEVATeva Pharmaceutical Industries2.7777 of 5 stars$17.40+0.2%N/A+87.6%$19.71B$15.85B-20.4737,851BGNEBeiGene3.0741 of 5 stars$192.32-6.2%N/A+0.0%$18.72B$2.46B-37.8610,600Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageMRNAModerna4.5631 of 5 stars$43.16+1.0%N/A-51.9%$16.59B$6.85B-7.425,600Analyst ForecastOptions VolumeGap DownSMMTSummit Therapeutics2.1933 of 5 stars$21.89+0.6%N/A+884.4%$16.14B$700,000.00-78.18105Gap UpVTRSViatris1.3727 of 5 stars$13.12+0.2%N/A+39.9%$15.66B$15.05B-17.7338,000Insider SellingGMABGenmab A/S4.4263 of 5 stars$22.88-1.4%N/A-35.6%$15.14B$19.84B22.212,204Short Interest ↑PCVXVaxcyte3.3295 of 5 stars$102.30-1.3%N/A+73.3%$12.75BN/A-22.24160News CoverageRDYDr. Reddy's Laboratories1.3454 of 5 stars$14.82-1.2%N/A+6.7%$12.37B$299.87B23.6727,048Analyst DowngradeShort Interest ↑SRPTSarepta Therapeutics4.9455 of 5 stars$117.29-0.5%N/A+26.0%$11.20B$1.64B93.831,314Analyst UpgradeCTLTCatalent2.8783 of 5 stars$59.67+0.4%N/A+48.7%$10.83B$4.38B-26.4016,900Analyst UpgradeInsider SellingNews Coverage Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Moderna Alternatives Summit Therapeutics Alternatives Viatris Alternatives Genmab A/S Alternatives Vaxcyte Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Catalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BHVN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BHVN Stock Alerts